{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T15:05:25Z","timestamp":1793718325094,"version":"4.6.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["134013\\u2010CSDG\\u201019\\u2010163\\u201001\\u2010TBG"],"award-info":[{"award-number":["134013\\u2010CSDG\\u201019\\u2010163\\u201001\\u2010TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032128","name":"Taiho Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.annonc.2024.11.017","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T11:45:31Z","timestamp":1733917531000},"page":"414-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9777-6221","authenticated-orcid":false,"given":"L.","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"DiToro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-7551","authenticated-orcid":false,"given":"A.","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Bridgewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Silhavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3962-5932","authenticated-orcid":false,"given":"V.","family":"Wacheck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Halim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-6072","authenticated-orcid":false,"given":"F.","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2024.11.017_bib1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2024.11.017_bib2","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.annonc.2024.11.017_bib3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2024.11.017_bib4","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rod\u00f3n","year":"2024","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.annonc.2024.11.017_bib5","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2024.11.017_bib6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2024.11.017_bib7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.annonc.2024.11.017_bib8","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.annonc.2024.11.017_bib9","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a004002","article-title":"Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy","volume":"5","author":"Krook","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"3","key":"10.1016\/j.annonc.2024.11.017_bib10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","article-title":"Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma","volume":"19","author":"Krook","year":"2020","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.annonc.2024.11.017_bib11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2024.11.017_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/PO.20.00178","article-title":"Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations","volume":"5","author":"Varghese","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2024.11.017_bib13","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/2159-8290.CD-20-1669","article-title":"FGFR2 extracellular domain in-frame deletions are therapeutically targetable genomic alterations that function as oncogenic drivers in cholangiocarcinoma","volume":"11","author":"Cleary","year":"2021","journal-title":"Cancer Discov"},{"issue":"22","key":"10.1016\/j.annonc.2024.11.017_bib14","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1158\/0008-5472.CAN-19-2568","article-title":"Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors","volume":"80","author":"Sootome","year":"2020","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2024.11.017_bib15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/j.annonc.2024.11.017_bib19","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2024.11.017_bib20","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-15-1246","article-title":"High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial","volume":"6","author":"Pearson","year":"2016","journal-title":"Cancer Discov"},{"issue":"20","key":"10.1016\/j.annonc.2024.11.017_bib21","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-21-1414","article-title":"Circulating tumor DNA analysis detects FGFR2 amplification and concurrent genomic alterations associated with FGFR inhibitor efficacy in advanced gastric cancer","volume":"27","author":"Jogo","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.annonc.2024.11.017_bib22","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer","volume":"19","author":"Andr\u00e9","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2024.11.017_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-46586-y","article-title":"Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer","volume":"13","author":"Saridogan","year":"2023","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.annonc.2024.11.017_bib24","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/1078-0432.CCR-12-3898","article-title":"FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547","volume":"19","author":"Xie","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.annonc.2024.11.017_bib25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jhep.2022.11.030","article-title":"Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma","volume":"78","author":"Kendre","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"8","key":"10.1016\/j.annonc.2024.11.017_bib26","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1593\/neo.121106","article-title":"The N550K\/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors","volume":"15","author":"Byron","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.annonc.2024.11.017_bib27","article-title":"Oncogenic RAS drives resistance to pemigatinib in cholangiocarcinoma harboring a FGFR2 delins disrupting ligand binding","volume":"7","author":"Lim","year":"2023","journal-title":"JCO Precis Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2024.11.017_bib28","doi-asserted-by":"crossref","first-page":"430","DOI":"10.6004\/jnccn.2021.7121","article-title":"Robust response to futibatinib in a patient with metastatic FGFR-addicted cholangiocarcinoma previously treated using pemigatinib","volume":"20","author":"Rengan","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.annonc.2024.11.017_bib29","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.annonc.2024.11.017_bib30","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2023.10.041","article-title":"Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma","volume":"80","author":"DiPeri","year":"2024","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.annonc.2024.11.017_bib31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.annonc.2024.11.017_bib32","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/1078-0432.CCR-24-1834","article-title":"Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven malignancies","volume":"30","author":"Facchinetti","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"19","key":"10.1016\/j.annonc.2024.11.017_bib33","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-23-3780","article-title":"Clinical value of liquid biopsy in patients with FGFR2 fusion-positive cholangiocarcinoma during targeted therapy","volume":"30","author":"Gonz\u00e1lez-Medina","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.annonc.2024.11.017_bib34","first-page":"2854","article-title":"A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma","volume":"9","author":"Goyal","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2024.11.017_bib35","first-page":"2854","article-title":"Molecular profiling in\u00a0daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.annonc.2024.11.017_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.988527","article-title":"Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: a prospective multicenter study","volume":"12","author":"Takada","year":"2022","journal-title":"Front Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424049767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424049767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:13:24Z","timestamp":1762319604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424049767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0923753424049767"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.11.017","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}